<div id="readability-page-1"><p><span>Pacira BioSciences (NASDAQ:PCRX - Get Free Report)</span> was upgraded by stock analysts at Barclays to a &#34;hold&#34; rating in a research note issued to investors on Monday,Zacks.com reports.</p><div><p><span></span><span>Get <strong>Pacira BioSciences</strong> alerts:</span></p></div><p>PCRX has been the topic of a number of other reports. Wall Street Zen upgraded shares of Pacira BioSciences from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. HC Wainwright  reissued a &#34;buy&#34; rating and issued a $38.00 price target on shares of Pacira BioSciences in a report on Monday, November 17th. Truist Financial lowered their price objective on shares of Pacira BioSciences from $30.00 to $28.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, November 7th. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Pacira BioSciences in a report on Monday. Finally, Zacks Research raised Pacira BioSciences from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, August 14th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one  has given a Sell rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Hold&#34; and an average target price of $28.20.</p><p><b>View Our Latest Stock Report on Pacira BioSciences</b></p><h2>Pacira BioSciences Stock Performance</h2><p>Shares of NASDAQ:PCRX opened at $24.77 on Monday. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. Pacira BioSciences has a 1-year low of $18.17 and a 1-year high of $27.64. The stock has a market capitalization of $1.07 billion, a P/E ratio of 55.05 and a beta of 0.23. The business has a 50-day moving average price of $23.09 and a two-hundred day moving average price of $24.13. </p><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a net margin of 2.99% and a return on equity of 12.82%. The company had revenue of $179.52 million for the quarter, compared to analyst estimates of $182.86 million. During the same quarter last year, the firm earned $0.79 EPS. The company's revenue for the quarter was up 6.5% on a year-over-year basis.  Equities analysts predict that  Pacira BioSciences will post 2.41 earnings per share for the current year. </p><h2>Insider Transactions at Pacira BioSciences</h2><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 3,960 shares of Pacira BioSciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $24.09, for a total value of $95,396.40. Following the sale, the insider owned 178,367 shares of the company's stock, valued at $4,296,861.03. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own  6.40% of the company's stock. </p><h2>Institutional Investors Weigh In On Pacira BioSciences</h2><p>Institutional investors have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new position in shares of  Pacira BioSciences during the 1st quarter worth approximately $32,506,000.  Doma Perpetual Capital Management LLC lifted its position in shares of  Pacira BioSciences by 49.7% in the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company's stock worth $69,613,000 after purchasing an additional 897,255 shares in the last quarter.  Balyasny Asset Management L.P. boosted its holdings in  Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company's stock worth $50,925,000 after purchasing an additional 565,288 shares during the last quarter.  American Century Companies Inc. grew its position in  Pacira BioSciences by 392.2% in the first quarter. American Century Companies Inc. now owns 667,423 shares of the company's stock valued at $16,585,000 after purchasing an additional 531,831 shares in the last quarter.  Finally, Nuveen LLC bought a new position in  Pacira BioSciences in the first quarter valued at $12,884,000. Institutional investors own  99.73% of the company's stock. </p><h2>Pacira BioSciences Company Profile</h2> (Get Free Report)<p>Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.</p><h2>See Also</h2><ul><li>Five stocks we like better than Pacira BioSciences</li><li>How to trade penny stocks: A step-by-step guide</li><li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li><li>ESG Stocks, What Investors Should Know</li><li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pacira BioSciences Right Now?</h2><p>Before you consider Pacira BioSciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p><p>While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PCRX

<p>Barclays upgraded Pacira BioSciences (NASDAQ:PCRX) to a "hold" rating. Other analysts have varied ratings: Wall Street Zen upgraded to "strong-buy," HC Wainwright maintained "buy" with a $38 target, Truist Financial lowered target to $28 but kept "buy," Weiss Ratings reiterated "sell," and Zacks Research upgraded to "hold." The stock opened at $24.77 with a market cap of $1.07 billion.</p>

Pacira BioSciences (NASDAQ:PCRX) Upgraded to Hold at Barclays